Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

199.65 +6.56 (+3.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 971,118
Open 195.33
Bid (Size) 196.70 (1)
Ask (Size) 199.65 (1)
Prev. Close 193.09
Today's Range 194.50 - 199.78
52wk Range 187.16 - 468.55
Shares Outstanding 147,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment
Eisai finished submitting its application for lecanemab, another anti-amyloid drug. 
Via Investor's Business Daily
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga

Performance

YTD
-18.22%
-18.22%
1 Month
-9.43%
-9.43%
3 Month
-4.83%
-4.83%
6 Month
-22.37%
-22.37%
1 Year
-30.33%
-30.33%

More News

Read More
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
Via Benzinga
Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
From MedRhythms
Via Business Wire
Stock Market Jumps, Then Dives After Fed Rate Hikes As Treasury Yields Soar: Weekly Review
Via Investor's Business Daily
Looking Into Biogen's Return On Capital Employed
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Via Benzinga
Read Why Biogen Sares Are Trading Higher After Q1 Earnings
Via Benzinga
Biogen Pops On New Plans For Its Embattled Alzheimer's Drug, Aduhelm
Via Investor's Business Daily
Recap: Biogen Q1 Earnings
Via Benzinga
BIIB Stock Treks Higher Amid News That Biogen CEO Michel Vounatsos Is Stepping Down
Via InvestorPlace
Biogen Inc. Q1 Earnings Miss Estimates
Via Talk Markets
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Via Benzinga
Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder
Via Benzinga
Biogen Fails To Convince Benefits Of Alzheimer's Drug To European Regulator
Via Benzinga
Why Biogen Stock Looks 'Too Good To Ignore,' According To One Analyst
Via Investor's Business Daily
Earnings Preview For Biogen
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Via Benzinga
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
From Sage Therapeutics, Inc.
Via Business Wire
If You Invested $100 In Biogen 15 Years Ago, Here's How Much You Would Have Today
Via Benzinga
Analyst Ratings for Biogen
Via Benzinga
Biogen Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Via InvestorPlace
Why This Analyst Believes Biogen Is 'Too Good to Ignore'
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.